16. Dayrell-Hart, B. et al.: Efficacy and safety of felbamate as an anticonvulsant in dogs with refractory seizures (abst.).
J. Vet. Intern. Med. 10 (3):174; 1996.
17. Johannessen, S.I. et al.: Therapeutic drug monitoring of the newer antiepileptic drugs. Ther. Drug Monit. 25 (3):347-363;
2003.
18. Bazil, C.W.: New antiepileptic drugs. Neurologist 8 (2):71-81; 2002.
19. Ruehlmann, D. et al.: Treatment of partial seizures and seizure-like activity with felbamate in six dogs. J. Small Anim.
Pract. 42 (8):403-408; 2001.
20. Radulovic, L.L. et al.: Disposition of gabapentin (neurontin) in mice, rats, dogs, and monkeys. Drug Metab. Dispos. 23 (4):441-448;
1995.
21. Vollmer, K.O. et al.: Pharmacokinetics and metabolism of gabapentin in rat, dog and man. Drug Res. 36 (5):830-839; 1986.
22. Leppik, I.E.: The place of levetiracetam in the treatment of epilepsy. Epilepsia 42 (suppl. 4):44-45; 2001.
23. Hovinga, C.A.: Levetiracetam: A novel antiepileptic drug. Pharmacotherapy 21 (11):1375-1388; 2001.
24. Shorvon, S.D.; van Rijckevorsel, K.: A new antiepileptic drug (editorial). J. Neurol. Neurosurg. Psychiatry 72 (4):426-429;
2002.
25. Krakow, K. et al.: Long-term continuation of levetiracetam in patients with refractory epilepsy. Neurology 56 (12):1772-1774;
2001.
26. Morrell, M.J. et al.: The KEEPER trial: Levetiracetam adjunctive treatment of partial-onset seizures in an open-label community-based
study. Epilepsy Res. 54 (2-3):153-161; 2003.
27. Isoherranen, N. et al.: Pharmacokinetics of levetiracetam and its enantiomer (R)-alpha-ethyl-2-oxo-pyrrolidine acetamide
in dogs. Epilepsia 42 (7):825-830; 2001.
28. Steinberg, M.; Faissler, D.: Levetiracetam therapy for long-term idiopathic epileptic dogs (abst.). J. Vet. Intern. Med.
18 (3):410; 2004.
29. Oommen, K.J.; Mathews, S.: Zonisamide: A new antiepileptic drug. Clin. Neuropharmacol. 22 (4):192-200; 1999.
30. Leppik, I.E.: Zonisamide. Epilepsia 40 (suppl. 5):S23-S29; 1999.
31. Mori, A. et al.: The anticonvulsant zonisamide scavenges free radicals. Epilepsy Res. 30 (2):153-158; 1998.
32. Faught, E. et al.: Randomized controlled trial of zonisamide for the treatment of refractory partial-onset seizures. Neurology
57 (10):1774-1779; 2001.
33. Leppik, I.E. et al.: Efficacy and safety of zonisamide: Results of a multicenter study. Epilepsy Res. 14 (2):165-173; 1993.
34. Matsumoto, K. et al.: Absorption, distribution and excretion of 3-(sulfamoyl [14C] methyl)-1,2-benzisoxazole (AD-810) in rats, dogs and monkeys and of AD-810 in men. Drug Res. 33 (7):961-968; 1983.
35. Shinoda, M. et al.: The necessity of adjusting the dosage of zonisamide when coadministered with other antiepileptic drugs.
Biol. Pharm. Bull. 19 (8):1090-1092; 1996.
36. Dewey, C.W. et al.: Zonisamide therapy for refractory idiopathic epilepsy in dogs. JAAHA 40 (4):285-291; 2004.
37. Walker, R.M. et al.: Chronic toxicity of the anticonvulsant zonisamide in beagle dogs. Fundam. Appl. Toxicol. 11 (2):333-342;
1988.
38. Schicht, S. et al.: Pharmacokinetics of oxcarbazepine in the dog. J. Vet. Pharmacol. Ther. 19 (1):27-31; 1996.
39. Reddy, D.S.: Tiagabine: A potent antiepileptic drug with selective GABA uptake inhibitory effect. Indian J. Pharmacol. 30:141-151;
1998.
40. Streeter, A.J. et al.: Pharmacokinetics and bioavailability of topiramate in the beagle dog. Drug Metab. Dispos. 23 (1):90-93;
1995.
|
Featuring Information from:
